Clinical Trial

Comprehensive Assessment of Neurodegeneration and Dementia

Study acronym: COMPASS-ND
Recruiting
View on ClinicalTrials.gov →
Summary
This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are/will be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2018-01-11; most recent amendment 2026-01-15.
Trial Details
NCT Number NCT03402919
Lead Sponsor McGill University
Collaborators: Canadian Institutes of Health Research (CIHR), Alzheimer Society of Canada, Sanofi, New Brunswick Health Research Foundation, Saskatchewan Health Research Foundation, Michael Smith Foundation for Health Research, Nova Scotia Health Research Foundation, Eli Lilly and Company, Canadian Nurses Foundation (CNF), Ontario Brain Institute, Pfizer, Canadian Consortium on Neurodegeneration in Aging
Conditions Dementia, Mild Cognitive Impairment (MCI), Subjective Cognitive Impairment, Parkinson's Disease (PD), Lewy Body Disease(LBD), Mixed Dementia, Frontotemporal Dementia (FTD), Alzheimer Disease (AD) +2 more
Enrollment 1,573 participants
Start Date 2016-06
Primary Completion 2023-11 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-20